Cost-Effectiveness of Extended and One-Time Screening Versus No Screening for Non-Valvular Atrial Fibrillation in the USA

ConclusionsOur analysis suggests that, screening the general population at age 75  years for NVAF is cost effective at a WTP threshold of $100,000. Both extended screening and one-time screening for NVAF are expected to provide health benefits at an acceptable cost.
Source: Applied Health Economics and Health Policy - Category: Health Management Source Type: research